AcuCort AB (Spotlight Stock Market: ACUC) today announces that the European Patent Office (EPO) has approved the patent application “Dexamethasone ODF”, jointly owned by AcuCort and the former manufacturing partner LTS Lohmann. In August 2019, AcuCort introduced the registered trademark ISICORT® for the drug candidate previously called Dexa ODF.
AcuCort has previously reported that EPO intended to approve the EU patent application No. 15790542.3. The patent primarily describes the formulation, the manufacturing process and the intended area of use for ISICORT®. The now granted patent will be validated and provide protection in 16 European countries including Turkey until November 2035.
In addition to Europe, the corresponding patent applications have been filed in the US, Japan, China, Hong Kong, Canada, Brazil and Australia.
AcuCort’s drug candidate ISICORT® is already protected by the patent “Acute Glucocorticoid Therapy”. This patent describes medical self-treatment with glucocorticoids in emergency situations when no medical personnel is available. The patent is granted in 31 countries, including in Europe and the US, and is valid to 2025, except in the US, where it is valid until the end of 2028.
“This is expected and very good news. AcuCort already has patent protection for the company’s drug candidate ISICORT® in Europe, but the new patent ‘Dexamethasone ODF’ granted by the European Patent Office means broader protection as well an extended term of protection. This will facilitate the commercialization of ISICORT®”, says Mats Lindfors, CEO of AcuCort AB.
For more information, please contact
Mats Lindfors, CEO, AcuCort AB
Phone: +46 70 790 58 15
E-mail: mats.lindfors@acucort.se
About AcuCort AB
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance containing – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and Chemotherapy Induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Taken together, this strengthens the company’s assessment that the time until commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Learn more at www.acucort.com.